nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S: Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors
July 10, 2022 10:02 ET | Novo Nordisk A/S
Data presented today show a reduction in treated spontaneous and traumatic bleeds and mean annualised bleeding rate (ABR) of 1.7 with concizumab1 London, UK, 10 July 2022 – Novo Nordisk announced the...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S: Share repurchase programme
July 04, 2022 08:54 ET | Novo Nordisk A/S
Bagsværd, Denmark, 4 July 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S – Share repurchase programme
June 27, 2022 07:29 ET | Novo Nordisk A/S
Bagsværd, Denmark, 27 June 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH
June 22, 2022 05:00 ET | Novo Nordisk A/S
Paris, France and Bagsværd, Denmark, 22 June 2022 – Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, today announced...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S – Share repurchase programme
June 20, 2022 08:44 ET | Novo Nordisk A/S
Bagsværd, Denmark, 20 June 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S – Share repurchase programme
June 13, 2022 09:00 ET | Novo Nordisk A/S
Bagsværd, Denmark, 13 June 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S: Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency
June 12, 2022 12:31 ET | Novo Nordisk A/S
Investigational phase 3 data for Sogroya® (somapacitan) injection in children with growth hormone deficiency presented today at the ENDO 2022 Congress1 Atlanta, Georgia (US), 12 June 2022 – Today,...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S – Share repurchase programme
June 07, 2022 13:52 ET | Novo Nordisk A/S
Bagsværd, Denmark, 07 June 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk – major shareholder announcement
June 07, 2022 07:26 ET | Novo Nordisk A/S
Bagsværd, Denmark, 7 June 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 31 May 2022 holds B shares equal to below 5%...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk achieves primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin glargine U100 in ONWARDS 1
June 03, 2022 03:30 ET | Novo Nordisk A/S
Bagsværd, Denmark, 3 June 2022 – Novo Nordisk today announced headline results from the main phases of ONWARDS 1 (52 weeks) and ONWARDS 6 (26 weeks) phase 3a trials with once-weekly insulin icodec. ...